Oct. 4 at 11:49 PM
$MLTX Here are the competitors:
*(Cosentyx) generated
$6.141 billion in annual revenue for the full year 2024
*(Bimzelx) sales reached €607 million (
$636 million) in 2024, and the drug is projected to achieve blockbuster status, with peak sales forecast to exceed €7 billion in the coming years.
*(Humira) annual sales peaked around
$21.2 billion in 2022 before losing patent protection, leading to a sharp decline with global sales falling 32% to approximately
$14.4 billion in 2023.
sonelokimab Is likely to get FDA approved as this market for HS needs more forms of treatment for people that are tolerant.
Remember they turned down a 3 billion offer from Merck, and management is confident about their drug.
